Dupilumab and Tezepelumab: Advancements in Severe Asthma Treatment
In the realm of severe asthma management, two biologic treatments, Dupilumab and Tezepelumab, have shown promising advancements. Recent studies presented at the 2025 AAAAI/WAO conference highlighted their efficacy but also revealed low overall biologic adherence rates.
Dupilumab: Mechanism and Uses
Dupilumab, marketed as dupixent, is a groundbreaking treatment that targets a specific protein involved in inflammation. Unlike customary immunosuppressants, Dupixent does not suppress the immune system. Instead, it calms an overreactive immune system by blocking the action of certain interleukins.
Dupilumab is used to treat a variety of conditions,including:
- Eczema (atopic dermatitis)
- Eosinophilic or oral-corticosteroid-dependent asthma
- Chronic rhinosinusitis with nasal polyps
- COPD with an eosinophilic phenotype
- Eosinophilic esophagitis (EOE)
- Prurigo nodularis
Patients typically self-administer Dupilumab via subcutaneous injection every 1 to 4 weeks,depending on the condition being treated.
tezepelumab: Mechanism and Uses
Tezepelumab, another biologic treatment, has also gained traction for severe asthma. It’s mechanism involves blocking a different pathway in the immune system, offering an alternative approach to managing the condition.
Adherence Rates: A Challenge
Despite the promising results of these biologic treatments,adherence rates remain a concern. Studies from the 2025 AAAAI/WAO conference indicated that overall biologic adherence rates are low. This poses a important challenge in achieving optimal patient outcomes.
Side Effects and Warnings
Like any medication, Dupilumab comes with potential side effects. Common side effects include injection site reactions and eye-related issues. Serious side effects, though rare, may require medical attention. Patients should be aware of these potential reactions and consult their healthcare provider if they experience any concerning symptoms.
| Condition Treated | Dupilumab Dosage | Tezepelumab Dosage |
|—————————–|—————————|—————————–|
| Eczema (AD) | Subcutaneous injection | Not specified |
| Asthma | Subcutaneous injection | Subcutaneous injection |
| Chronic Rhinosinusitis | Subcutaneous injection | Subcutaneous injection |
| COPD | Subcutaneous injection | Subcutaneous injection |
| Eosinophilic Esophagitis | Subcutaneous injection | Not specified |
| Prurigo nodularis | Subcutaneous injection | Not specified |
Conclusion
While Dupilumab and Tezepelumab represent significant advancements in the treatment of severe asthma and related conditions, ensuring patient adherence to these therapies remains crucial.Healthcare providers and patients must work together to optimize treatment outcomes and manage potential side effects effectively.
For more detailed information on Dupilumab, visit Drugs.com.
Exploring Dupilumab and Tezepelumab: Advancements in Treating Severe Asthma
In the realm of severe asthma management, two biologic treatments, Dupilumab and Tezepelumab, have shown promising advancements.Recent studies presented at the 2025 AAAAI/WAO conference highlighted their efficacy but also revealed low overall biologic adherence rates.
An Interview with Dr. Emily Hartfield, Specialist in Immunology
Senior Editor (SE): welcome, Dr. Emily Hartfield. Could you start by explaining how Dupilumab differs from traditional asthma treatments?
Dupilumab: Mechanism and Uses
Dr. Emily Hartfield (EH): Certainly! Dupilumab, marketed as Dupixent, is a groundbreaking treatment that targets a specific protein involved in inflammation. Unlike customary immunosuppressants,Dupixent dose not suppress the immune system. Instead, it calms an overreactive immune system by blocking the action of certain interleukins.
SE: What conditions does Dupilumab treat, and how is it administered?
EH: Dupilumab is used to treat a variety of conditions, including eczema (atopic dermatitis), eosinophilic or oral-corticosteroid-dependent asthma, chronic rhinosinusitis with nasal polyps, COPD with an eosinophilic phenotype, eosinophilic esophagitis (EOE), and prurigo nodularis. Patients typically self-administer Dupilumab via subcutaneous injection every 1 to 4 weeks, depending on the condition being treated.
Tezepelumab: mechanism and Uses
SE: Can you tell us about Tezepelumab and how it differs from Dupilumab?
EH: Tezepelumab is another biologic treatment that has gained traction for severe asthma. Unlike Dupilumab, it blocks a different pathway in the immune system, offering an choice approach to managing the condition.
Adherence Rates: A Challenge
SE: Given the promising results with both biologics, why do adherence rates remain a concern?
EH: Despite the promising results, studies from the 2025 AAAAI/WAO conference indicated that overall biologic adherence rates are low, posing a important challenge in achieving optimal patient outcomes. Ensuring patient adherence requires a collaborative effort between healthcare providers and patients to monitor and optimize treatment outcomes.
side Effects and Warnings
SE: Are there any notable side effects that patients should be aware of when taking Dupilumab?
EH: Like any medication, Dupilumab comes with potential side effects. Common side effects include injection site reactions and eye-related issues. Serious side effects are rare but may require medical attention. patients should be aware of these potential reactions and consult their healthcare provider if they experience any concerning symptoms.
SE: How do the dosages for Dupilumab and Tezepelumab compare?
EH: Both Dupilumab and Tezepelumab are administered via subcutaneous injection. The specific dosages can vary depending on the condition being treated. for example, patients with eczema (AD), asthma, chronic rhinosinusitis, COPD, eosinophilic esophagitis, and prurigo nodularis typically follow a set schedule. Though, some conditions do not have specified dosages for tezepelumab, indicating ongoing research and optimization.
Conclusion
SE: What is the key takeaway for healthcare providers and patients regarding these treatments?
EH: The key takeaway is that while dupilumab and Tezepelumab represent significant advancements in treating severe asthma and related conditions, ensuring patient adherence remains crucial. Healthcare providers and patients must work together to optimize treatment outcomes and manage potential side effects effectively. For more detailed data on Dupilumab, you can visit Drugs.com. thank you, Dr. Hartfield, for your insights.
